Aclaris Therapeutics (ACRS) Tops Q3 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $1.36 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• Kushner: conversations between U.S. and different areas of Iran govt are more robust than it has every been
• Eternity Founders Mohamad Al-Shami and Omar Abu Ghoush Announce US$1 Million Valuation